nach oben

Journal of Neuro-Oncology

Erschienen in:

01.11.2008 | Laboratory Investigation - human/animal tissue

CD133 identifies perivascular niches in grade II–IV astrocytomas

verfasst von: Karina Christensen, Henrik D. Schrøder, Bjarne W. Kristensen

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to investigate the localization and distribution of the putative brain tumour stem cell marker CD133 in formalin fixed paraffin embedded astrocytomas. A retrospective analysis of 114 grade II, III and IV astrocytomas was undertaken. The immunohistochemical expression of CD133 in paraffin sections was analysed using morphometry. In all grades, CD133 was expressed on tumour and endothelial cells. Tumour cells were found in perivascular niches, as dispersed single cells and in pseudopalisade formations around necrosis. There was no correlation between the mean volume fraction of CD133⁺ niches and all CD133⁺ tumour cells and tumour grade. However, the volume fraction of CD133⁺ blood vessels increased significantly from 0.4% in diffuse astrocytomas to 2.2% in glioblastomas. Neither of them was related to patient survival. Double immunofluorescence stainings showed that the CD133⁺ niches both contained CD133⁺ cells with and without co-expression of the intermediate filament protein marker nestin, and only few CD133⁺/MIB-1⁺ proliferating cells were found. In conclusion, a CD133⁺ perivascular stem cell-like entity exists in astrocytomas. CD133⁺ tumour vessels may play an important role in a brain tumour stem cell context, while CD133 alone does not appear to be a specific tumour stem cell marker related to patient survival.

Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737. doi:10.1038/nm0797-730 PubMedCrossRef

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648. doi:10.1038/367645a0 PubMedCrossRef

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988. doi:10.1073/pnas.0530291100 PubMedCrossRef

Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61:8664–8667PubMed

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037. doi:10.1158/0008-5472.CAN-06-2030 PubMedCrossRef

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03128 PubMedCrossRef

Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N et al (2004) Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 304:1338–1340. doi:10.1126/science.1095505 PubMedCrossRef

Palmer TD, Willhoite AR, Gage FH (2000) Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425:479–494. doi :10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3PubMedCrossRef

10.

Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S et al (2004) Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 427:740–744. doi:10.1038/nature02301 PubMedCrossRef

11.

Fuchs E, Tumbar T, Guasch G (2004) Socializing with the neighbors: stem cells and their niche. Cell 116:769–778. doi:10.1016/S0092-8674(04)00255-7 PubMedCrossRef

12.

Gilbertson RJ, Rich JN (2007) Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733–736. doi:10.1038/nrc2246 PubMedCrossRef

13.

Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66:4553–4557. doi:10.1158/0008-5472.CAN-05-3986 PubMedCrossRef

14.

Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N et al (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123–129. doi:10.1158/1078-0432.CCR-07-0932 PubMedCrossRef

15.

Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82. doi:10.1016/j.ccr.2006.11.020 PubMedCrossRef

16.

Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560–3564. doi:10.1158/0008-5472.CAN-06-4238 PubMedCrossRef

17.

Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through Vascular Endothelial Growth Factor. Cancer Res 66:7843–7848. doi:10.1158/0008-5472.CAN-06-1010 PubMedCrossRef

18.

Hemmati HD, Nakano I, Lazareff JA, Masterman Smith M, Geschwind DH, Bronner Fraser M et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178–15183. doi:10.1073/pnas.2036535100 PubMedCrossRef

19.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. doi:10.1038/nature05236 PubMedCrossRef

20.

Gal H, Makovitzki A, Amariglio N, Rechavi G, Ram Z, Givol D (2007) A rapid assay for drug sensitivity of glioblastoma stem cells. Biochem Biophys Res Commun 358:908–913. doi:10.1016/j.bbrc.2007.05.020 PubMedCrossRef

21.

Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J (2008) Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86:31–45. doi:10.1007/s11060-007-9439-7 PubMedCrossRef

22.

Shi SR, Liu C, Pootrakul L, Tang L, Young A, Chen R et al (2008) Evaluation of the value of frozen tissue section used as “gold standard” for immunohistochemistry. Am J Clin Pathol 129:358–366. doi:10.1309/7CXUYXT23E5AL8KQ PubMedCrossRef

23.

Fernebro E, Bendahl PO, Dictor M, Persson A, Ferno M, Nilbert M (2004) Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 111:921–928. doi:10.1002/ijc.20229 PubMedCrossRef

24.

Fernebro E, Dictor M, Bendahl PO, Ferno M, Nilbert M (2002) Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126:702–705PubMed

25.

Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17:790–797. doi:10.1038/modpathol.3800120 PubMedCrossRef

26.

Graham DI, Lantos PL (2002) Tumours of the nervous system. In: Graham DI, Lantos PL (eds) Greenfield’s neuropathology, vol 2, 7th edn. Arnold, Great Britain, pp 768–1052

27.

Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon

28.

Neckelmann K, Kristensen BW, Schroder HD (2004) Improved histopathological evaluation of gliomas using tissue fragments obtained by ultrasonic aspiration. Clin Neuropathol 23:47–52PubMed

29.

Silverman JF, Jones FD, Unverferth M, Berns L (1989) Cytopathology of neoplasms of the central nervous system in specimens obtained by the Cavitron Ultrasonic Surgical Aspirator. Acta Cytol 33:576–582PubMed

30.

Malhotra V, Malik R, Gondal R, Beohar PC, Parkash B (1986) Evaluation of histological appearance of tissues removed by cavitron ultrasonic surgical aspirator (CUSA). Acta Neurochir (Wien) 81:132–134. doi:10.1007/BF01401235 CrossRef

31.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon

32.

Kania G, Corbeil D, Fuchs J, Tarasov KV, Blyszczuk P, Huttner WB et al (2005) Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. Stem Cells 23:791–804. doi:10.1634/stemcells.2004-0232 PubMedCrossRef

33.

Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB et al (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319:15–26. doi:10.1007/s00441-004-1018-z PubMedCrossRef

34.

Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229–263PubMed

35.

Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K et al (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96:379–394PubMed

36.

Gundersen HJ (1992) Stereology: the fast lane between neuroanatomy and brain function—or still only a tightrope? Acta Neurol Scand Suppl 137:8–13PubMedCrossRef

37.

Gundersen HJ (1986) Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc 143:3–45PubMed

38.

Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, Englund E, Bengzon J et al (2007) CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res 67:5727–5736. doi:10.1158/0008-5472.CAN-07-0183 PubMedCrossRef

39.

Almqvist PM, Mah R, Lendahl U, Jacobsson B, Hendson G (2002) Immunohistochemical detection of nestin in pediatric brain tumors. J Histochem Cytochem 50:147–158PubMed

40.

Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM et al (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66:373–385PubMed

41.

Kanemura Y, Mori K, Sakakibara S, Fujikawa H, Hayashi H, Nakano A et al (2001) Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 68:141–152. doi:10.1046/j.1432-0436.2001.680208.x PubMedCrossRef

42.

Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S et al (2006) Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65:846–854. doi:10.1097/01.jnen.0000235118.75182.94 PubMedCrossRef

43.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951. doi:10.1158/0008-5472.CAN-05-2018 PubMedCrossRef

44.

von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M, Georgii A (1997) Tyramine amplification technique in routine immunohistochemistry. J Histochem Cytochem 45:1455–1459

45.

Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X (2008) Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS ONE. doi:10.1371/journal.pone.0001936

46.

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115. doi:10.1038/nature05384 PubMedCrossRef

47.

Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G et al (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965–969. doi:10.1136/jcp. 2004.016444 PubMedCrossRef

48.

Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, Chekenya M, Peters H, Lende G, Kalland KH, Oyan AM, Petersen K, Jonassen I, van der Kogel A, Feuerstein BG, Terzis AJ, Bjerkvig R, Enger PO (2006) Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 103:16466–16471. doi:10.1073/pnas.0607668103 PubMedCrossRef

49.

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al (2007) CD133⁺ and CD133⁻ glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010–4015. doi:10.1158/0008-5472.CAN-06-4180 PubMedCrossRef

50.

Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA et al (2008) Identification of A2B5+CD133− tumor-initiating cells in adult human gliomas. Neurosurgery 62:505–514. doi:10.1227/01.neu.0000316019.28421.95 PubMedCrossRef

51.

O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110. doi:10.1038/nature05372 PubMedCrossRef

Titel: CD133 identifies perivascular niches in grade II–IV astrocytomas
verfasst von: Karina Christensen
Henrik D. Schrøder
Bjarne W. Kristensen
Publikationsdatum: 01.11.2008
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2008
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9648-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma

Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy

Tissue transgluaminase 2 expression in meningiomas

Genomic changes in progression of low-grade gliomas

Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics